VRTX Vertex Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX

Price (delayed)

$548.05

Market cap

$138.91B

P/E Ratio

31.62

Dividend/share

N/A

EPS

$17.33

Enterprise value

$134.74B

?
Relative Growth: Rel. Growth: 79
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 33
Relative Profitability: Rel. Profitability: 96

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, ...

Highlights
Vertex Pharmaceuticals's quick ratio has increased by 27% YoY and by 7% QoQ
The EPS has increased by 23% year-on-year
VRTX's debt is up by 29% YoY
The price to earnings (P/E) is 21% more than the 5-year quarterly average of 26.1 and 13% more than the last 4 quarters average of 27.9
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vrtx.com
Peers: GILD ABBV MRK BMY

Key stats

What are the main financial stats of VRTX

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
1.44%
1 week
8.36%
1 month
13.7%
1 year
37.89%
YTD
20.89%
QTD
10.33%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$12.59B
Gross profit
$10.82B
Operating income
$4.78B
Net income
$4.41B
Gross margin
86%
Net margin
35%
The operating income has grown by 22% year-on-year and by 2% since the previous quarter
Vertex Pharmaceuticals's net income has increased by 21% YoY
VRTX's net margin is up by 10% YoY
The gross profit has grown by 10% YoY and by 2.7% from the previous quarter

Price vs fundamentals

How does VRTX's price correlate with its fundamentals

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
VRTX P/E details
P/E
31.62
P/B
6.87
P/S
11.05
EV/EBIT
25.51
EV/EBITDA
24.48
EV/Sales
10.7
The EPS has increased by 23% year-on-year
The price to earnings (P/E) is 21% more than the 5-year quarterly average of 26.1 and 13% more than the last 4 quarters average of 27.9
The equity has grown by 18% YoY and by 4.6% from the previous quarter
The stock's price to book (P/B) is 15% more than its last 4 quarters average of 6.0 and 13% more than its 5-year quarterly average of 6.1
The price to sales (P/S) is 18% more than the 5-year quarterly average of 9.4 and 18% more than the last 4 quarters average of 9.4
VRTX's revenue is up by 10% YoY and by 3% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on sales has increased by 9% year-on-year
VRTX's return on assets is up by 6% year-on-year
The return on equity has grown by 5% year-on-year but it has declined by 2.5% since the previous quarter
The return on invested capital has declined by 2.2% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's quick ratio has increased by 27% YoY and by 7% QoQ
Vertex Pharmaceuticals's current ratio has increased by 27% YoY and by 6% from the previous quarter
VRTX's debt is 90% lower than its equity
VRTX's debt is up by 29% YoY
The equity has grown by 18% YoY and by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.